First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, earl…
seekingalpha.com

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
No analyst coverage available for this stock.
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, earl…

No company information available